SRC and chronic myelogenous leukemia, BCR-ABL1 positive: In this study, we applied two SFK-targeted inhibitors: dasatinib, approved by the FDA for chronic myeloid leukemia 36, and NXP900, a novel SRC/YES1-inhibitor currently undergoing clinical trial (NCT05873686).